Results 11 to 20 of about 180,170 (299)

Multiple myeloma in people of working age in Czechia, Germany, and Poland: findings from a qualitative interview study [PDF]

, 2023
Purpose The study sought to understand the experiences of working age adults with myeloma and their partner/family members, living in Czechia, Germany, and Poland.
Forbat, Liz
core   +1 more source

greenelab/multiple-myeloma-classifier: Reproducible Analysis for Multiple Myeloma Classifier [PDF]

, 2019
Reproducible Analysis for Multiple Myeloma Classifier <p>The release stores all instructions to reproduce the analysis for the training and evaluating of a multi-class classifier to detect <em>KRAS</em>, <em>NRAS</em>, and ...
Greg Way
core   +1 more source

Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy [PDF]

, 2022
The treatment for multiple myeloma has advanced significantly over the past few decades. Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma.
Huang, Shan, Tse, Gary, Xie, Bingxin, Liu, Tong, Zhang, Nan, Zheng, Yi, Liu, Zhiqiang   +6 more
core   +1 more source

Selinexor: Targeting a novel pathway in multiple myeloma

eJHaem, 2023
Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson   +9 more
doaj   +1 more source

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]

, 2013
Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
Papa, S, Rahemtulla, A, Chaidos, A, Barbarulo, A, Karadimitris, A, Iansante, V, Naresh, K, Haskard, DO, Bubici, C, Franzoso, G   +9 more
core   +1 more source

Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase

Clinical and Applied Thrombosis/Hemostasis, 2023
Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD, Adel Hajj Ali MD, Faiz Anwer MD, Raza Shahzad MD, Sandra Mazzoni DO, Louis Williams MD, Chakra Chaulagain MD, Betty Hamilton MD, Craig Sauter MD, Jack Khouri MD   +9 more
doaj   +1 more source

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Antibodies, 2017
2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Yu-Tzu Tai   +6 more
doaj   +1 more source

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

Cells, 2022
Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein, E. Bridget Kim, Noopur Raje   +2 more
doaj   +1 more source

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival [PDF]

, 2011
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
Hatton, CSR, Taylor Steve, Taylor, Stephen, Taylor, S, Lawrie Charles H, Saunders, NJ, Steve Taylor, Pezzella Francesco, Saunders Nigel J, Tramonti, D, Lawrie, CH, Wainscoat James S, Kusec, R, Pezzella, F, Tramonti Daniela, Nigel J Saunders, Hatton Christian SR, Chen, XH, Hatton, CS, Charles H Lawrie, Rajko Kušec, Littlewood, T, Erica Ballabio, Deborah Hay, Timothy Littlewood, Chi, J, Jacqueline Boultwood, Boultwood Jacqueline, Kušec Rajko, Jianxiang Chi, Chen Xiao-He, James S Wainscoat, Ballabio, E, Ballabio Erica, Chi Jianxiang, Xiao-He Chen, Littlewood Timothy, Francesco Pezzella, Christian SR Hatton, Wainscoat, JS, Hay Deborah, Pezzella, Francesco, Boultwood, Jacqueline, Hay, D, Boultwood, J, Daniela Tramonti   +45 more
core   +2 more sources

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

Haematologica, 2018
Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe.
Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass   +8 more
doaj   +1 more source